Inozyme Pharma, Inc.
Prognozy (mln)
| Okres |
2024-12-31 |
2025-12-31 |
2026-12-31 |
2027-12-31 |
2028-12-31 |
2029-12-31 |
| Przychód (średnia) |
0.00 |
0.00 |
1.06 |
35.83 |
102.63 |
187.98 |
| Przychód Δ r/r |
0.00% |
0.00% |
inf% |
3288.93% |
186.48% |
83.15% |
| Przychód (min) |
0.00 |
0.00 |
1.06 |
35.83 |
102.63 |
187.98 |
| Przychód (max) |
0.00 |
0.00 |
1.06 |
35.83 |
102.63 |
187.98 |
| EBITDA (średnia) |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
| EBIT (średnia) |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
| EBIT % |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
| Zysk netto (średni) |
-100.32 |
-89.90 |
-75.64 |
-47.01 |
-35.95 |
-8.27 |
| Zysk netto % |
-inf% |
-inf% |
-7155.48% |
-131.21% |
-35.03% |
-4.40% |
| EPS (średnia) |
-1.60 |
-1.43 |
-1.20 |
-0.85 |
-0.57 |
-0.13 |
| Liczba analityków (Przychody) |
0 |
0 |
6 |
6 |
2 |
5 |
| Liczba analityków (EPS) |
6 |
4 |
4 |
5 |
2 |
1 |
| symbol |
INZY |
INZY |
INZY |
INZY |
INZY |
INZY |